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Objective: To assess the efficacy of low-dose Cidofovir in the treat-
ment of BK virus associated nephropathy.
Method: Two adult kidney transplant recipients with biopsy-proven
BK nephropathy and persistent high viremia (>10,000 copies/ml)
despite 3-month reduction of immunosuppressive therapy were
treated by Cidofovir 0.5 mg/kg fortnightly for a total of 16 weeks
(8 doses). Clinical response was assessed by following BK viremia.
Results: No decrease in BK viremia was observed at any point dur-
ing cidofovir therapy (see figure). Creatinine clearance remained
stable during therapy and no side-effects of Cidofovir were ob-
served.
Conclusions: Low-dose Cidofovir therapy was not associated with
a clearance or with a significant decrease of BK viremia. This pilot
study does not confirm previous reports suggesting clinical efficacy
of Cidofovir for BK virus associated nephropathy.
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Background: Cytomegalovirus (CMV) disease remains an important
cause of morbidity after kidney transplantation and has been asso-
ciated with acute rejection, graft loss and other indirect effects.
A 3-month course of VGC prophylaxis reduces the incidence of CMV
disease. However, little is known about the indirect effects of late-
onset CMV disease after VGC prophylaxis.
Objective: To evaluate the impact and indirect consequences of
late-onset CMV disease after VGC prophylaxis in kidney transplant
recipients.
Methods: Retrospective analysis of 61 consecutive adult kidney
transplant recipient with positive CMV serology (donor or recipi-
ent) who received VGC prophylaxis for 3 months and completed
a follow-up of at least 2 years post-transplantation. Patients who
developed CMV disease within 1 year after transplantation were
compared to CMV disease-free patients for renal function (plasma
creatinine values) at 1, 6, 12 and 24 months and for the incidence
of graft loss, acute rejection, diabetes, cancer and opportunistic
infections.
Results: 8/61 (13%) patients developed CMV disease at a median of
131 days after transplantation (range: 98–220). The CMV incidence
in D+/R- high risk patients was 6/18 (33%), while it was 2/43 (5%) in
intermediate-risk patients (p < 0.01). All 8 patients were treated
by oral valganciclovir (median 39 days; range: 19–119) with a com-
plete resolution of CMV disease. As shown in the figure, there was
no difference in creatinine values between the two groups at any
time during follow-up. There was no graft loss, and the incidence
of acute rejection, cancer and opportunistic infections did not dif-
fer between the two groups. The incidence of post-transplant di-
abetes was higher (38% vs 15%) in patients with CMV disease, but
this difference was not significant (p = 0.4).
Conclusions: An incidence of 13% of late-onset CMV disease was
observed despite 3 months VGC prophylaxis. However, no indirect
consequences were found. Moreover, therapy of CMV disease by
oral VGC was effective and safe. Larger trials are needed to study
whether late-onset CMV disease is associated with indirect conse-
quences, as described with early-onset CMV.
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Background: BKV associated nephropathy is a major problem
among renal transplant recipients as it leads to graft loss. Iden-
tification and monitoring of high risk patients is crucial for the
induction of therapy and the survival of the graft.
Objectives: We examine the effectiveness of quantitative Real-
Time PCR to identify patients at high risk of BKVN and monitor the
efficacy of treatment, in order to avoid invasive methods.
Methods: From 7/2005 to 2/2008 231 paired samples (plasma and
urine) were sent to our lab for BKV viral load measurement. The
samples were drawn upon kidney dysfunction from 121 patients
that underwent renal transplantation at the transplant unit of
Laiko Hospital. On the basis of PCR positivity the patients were
classified into 3 groups. Group 1 (n=89) tested negative both in
plasma and urine. In Group 2 (n=22) BKV DNA was detected only in
urine while Group 3 patients (n=10) had DNAemia and viruria and
were treated with leflunomide along with reduction of immuno-
suppression.
Results: Group 1 and Group 2 patients never developed BKVN.
Group 2 patients had a median viral load of 2.6×104 copies/mL,
but had negative urine cytopathology or biopsy. Group 3 me-
dian viral load of DNAemia and viruria was respectively 3.9×104
copies/mL and 7.15×104 copies/mL. 80% of the patients had posi-
tive urine cytopathology and 100% had positive biopsy.
Upon treatment with leflunomide DNAemia resolved very quickly,
while viruria showed clearance or progressive reduction in 80%.
Two patients that showed multiple reactivations of the virus even-
tually resolved as well.
Conclusions: Viral load measurement in paired plasma and urine
samples is a sensitive and specific non invasive method for the
monitoring of BKV infection in RT recipients. Since the incidence of
